Notice: This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TORC vs. MNPR, ATOS, ENTA, IFRX, NLTX, SAVA, APLT, IVA, VERU, and LPTXShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Monopar Therapeutics (MNPR), Atossa Therapeutics (ATOS), Enanta Pharmaceuticals (ENTA), InflaRx (IFRX), Neoleukin Therapeutics (NLTX), Cassava Sciences (SAVA), Applied Therapeutics (APLT), Inventiva (IVA), Veru (VERU), and Leap Therapeutics (LPTX). These companies are all part of the "medical" sector. resTORbio vs. Monopar Therapeutics Atossa Therapeutics Enanta Pharmaceuticals InflaRx Neoleukin Therapeutics Cassava Sciences Applied Therapeutics Inventiva Veru Leap Therapeutics resTORbio (NASDAQ:TORC) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations. Which has more volatility and risk, TORC or MNPR? resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Which has better valuation & earnings, TORC or MNPR? Monopar Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioresTORbioN/AN/A-$82.74M-$2.41-0.38Monopar TherapeuticsN/AN/A-$8.40M-$1.97-13.11 Is TORC or MNPR more profitable? resTORbio's return on equity of -78.12% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets resTORbioN/A -78.12% -71.63% Monopar Therapeutics N/A -107.21%-87.57% Do institutionals & insiders have more ownership in TORC or MNPR? 46.2% of resTORbio shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 11.8% of resTORbio shares are owned by insiders. Comparatively, 34.9% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer TORC or MNPR? resTORbio received 99 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 72.41% of users gave Monopar Therapeutics an outperform vote while only 67.14% of users gave resTORbio an outperform vote. CompanyUnderperformOutperformresTORbioOutperform Votes14167.14% Underperform Votes6932.86% Monopar TherapeuticsOutperform Votes4272.41% Underperform Votes1627.59% Do analysts recommend TORC or MNPR? Monopar Therapeutics has a consensus price target of $27.33, indicating a potential upside of 5.86%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Monopar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TORC or MNPR? In the previous week, Monopar Therapeutics had 3 more articles in the media than resTORbio. MarketBeat recorded 3 mentions for Monopar Therapeutics and 0 mentions for resTORbio. Monopar Therapeutics' average media sentiment score of 0.85 beat resTORbio's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment resTORbio Neutral Monopar Therapeutics Positive SummaryMonopar Therapeutics beats resTORbio on 9 of the 15 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.17M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.5010.5989.9717.17Price / SalesN/A196.061,117.23117.03Price / CashN/A57.1643.0437.86Price / Book0.415.094.784.78Net Income-$82.74M$151.83M$120.31M$225.60M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.91+5.8%N/A-37.7%$33.17MN/A-0.50N/AGap UpMNPRMonopar Therapeutics1.9773 of 5 stars$26.26+3.5%$27.33+4.1%+1,178.2%$138.60MN/A-12.8810News CoverageGap UpATOSAtossa Therapeutics1.5129 of 5 stars$1.08-4.0%$7.00+551.2%+31.1%$135.24MN/A-5.208ENTAEnanta Pharmaceuticals4.0469 of 5 stars$6.34+5.1%$19.50+207.6%-29.4%$134.37M$67.64M-1.10145High Trading VolumeIFRXInflaRx2.4045 of 5 stars$2.25-4.7%$8.00+255.6%+51.4%$132.49M$168,498.00-2.1960Analyst ForecastNews CoveragePositive NewsNLTXNeoleukin TherapeuticsN/A$13.96+1.5%N/A+53.1%$131.20MN/A-7.5690News CoverageSAVACassava Sciences4.4047 of 5 stars$2.68-2.5%$111.50+4,060.4%-90.6%$128.94MN/A-1.9930News CoverageGap DownAPLTApplied Therapeutics4.5396 of 5 stars$1.11-3.9%$6.60+497.3%-71.5%$128.58M$9.99M-0.7130Analyst ForecastNews CoverageGap DownIVAInventiva3.1148 of 5 stars$2.39-2.4%$13.25+454.4%-46.0%$125.42M$15.62M0.00100VERUVeru1.9751 of 5 stars$0.80+11.2%$4.00+397.9%-3.4%$117.61M$14.09M-1.66189Earnings ReportAnalyst ForecastLPTXLeap Therapeutics1.2863 of 5 stars$2.99+1.4%$7.50+150.8%-7.9%$114.58M$1.50M-1.5340Positive NewsGap Down Related Companies and Tools Related Companies Monopar Therapeutics Alternatives Atossa Therapeutics Alternatives Enanta Pharmaceuticals Alternatives InflaRx Alternatives Neoleukin Therapeutics Alternatives Cassava Sciences Alternatives Applied Therapeutics Alternatives Inventiva Alternatives Veru Alternatives Leap Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TORC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
